Otto Phanstiel

Dr. Otto Phanstiel

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HDHana Douafer
Hana Douafer
VAVéronique Andrieu
Véronique Andrieu
Otto PhanstielOtto Phanstiel
Otto Phanstiel
jean Michel Bruneljean Michel Brunel
jean Michel Brunel

1 June 2016 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
ACAmy L. Cole
Amy L. Cole
SHSandra Hossain
Sandra Hossain
ACAlex M. Cole
Alex M. Cole
Otto PhanstielOtto Phanstiel
Otto Phanstiel

9 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AMAaron Muth
Aaron Muth
MMMeenu Madan
Meenu Madan
JAJennifer Julian Archer
Jennifer Julian Archer
NONicolette Ocampo
Nicolette Ocampo
LRLuis Rodriguez
Luis Rodriguez
Otto PhanstielOtto Phanstiel
Otto Phanstiel

3 August 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
EAEric T. Alexander
Eric T. Alexander
KMKelsey Mariner
Kelsey Mariner
JDJulia Donnelly
Julia Donnelly
Otto PhanstielOtto Phanstiel
Otto Phanstiel
SGSusan Gilmour
Susan Gilmour
Despite unprecedented advances in the treatment of cancer through the use of immune checkpoint blockade (ICB), responses are not universal and alternative strategies are needed to enhance responses to ICB. We have shown previously that a novel polyamine blocking therapy (PBT), consisting of cotreatment with α-difluoromethylornithine (DFMO) to block polyamine biosynthesis and a Trimer polyamine transport inhibitor, decreases myeloid-derived suppressor cells (MDSC) and M2-like tumor-associated macrophages (TAM). Both MDSCs and TAMs promote tumor progression, inhibit antitumor immunity, and limit the efficacy of ICB. In this study, we investigated the use of PBT to heighten therapeutic responses to PD-1 blockade in mice bearing 4T1 mammary carcinoma and B16F10 melanoma tumors. Whereas PBT inhibited primary tumor growth in both tumor models, 4T1 lung metastases were also dramatically decreased in mice treated with PBT. Reductions in MDSC and TAM subpopulations in 4T1 tumors from PBT-treated mice were accompanied by reduced cytoprotective autophagy only in tumor-infiltrating MDSC and macrophage subpopulations but not in the lung or spleen. PBT treatment blunted M2-like alternative activation of bone marrow–derived macrophages and reduced STAT3 activation in MDSC cultures while increasing the differentiation of CD80+, CD11c+ macrophages. PBT significantly enhanced the antitumor efficacy of PD-1 blockade in both 4T1 and B16F10 tumors resistant to anti–PD-1 monotherapy, increasing tumor-specific cytotoxic T cells and survival of tumor-bearing animals beyond that with PBT or PD-1 blockade alone. Our results suggest that cotreatment with DFMO and the Trimer polyamine transport inhibitor may improve the therapeutic efficacy of immunotherapies in patients with cancer with resistant tumors.

8 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VSVandana Sekhar
Vandana Sekhar
TAThomas Andl
Thomas Andl
Otto PhanstielOtto Phanstiel
Otto Phanstiel
The purpose of this study is to provide an increased understanding of the molecular mechanisms responsible for mammalian polyamine transport, a process that has been a long-standing ‘black box’ for the polyamine field. Here, we describe how ATP13A3, a P-type ATPase, functions as a polyamine transporter in response to different polyamine stimuli and polyamine-targeted therapies in highly proliferating pancreatic cancer cells. We assessed the expression, cellular localization and the response of the human ATP13A3 protein to polyamine treatments in different pancreatic cancer cell lines using Western blot and immunofluorescence microscopy. Using CRISPR mutagenesis and radiolabeled polyamine uptake assays, we investigated the role of ATP13A3 protein in polyamine transport. Highly metastatic cancer cells with high polyamine import express higher levels of the full-length ATP13A3 compared to cells with slow proliferation and low import activity. Highlighting its role in polyamine trafficking, the localization of ATP13A3 is altered in the presence of polyamine stimuli and polyamine-targeted therapies in these cells. Using CRISPR mutagenesis, we demonstrate that the first membrane-associated domain of this protein is critical and indispensable for its function as a spermidine and spermine transporter in cells. Further analysis of existing databases revealed that pancreatic cancer patients with high expression of ATP13A3 have decreased overall survival consistent with the role of intracellular polyamines in supporting tumor growth. Our studies shed light on the mysterious polyamine transport process in human cells and clearly establishes ATP13A3 as an intrinsic component of the spermidine and spermine transport system in humans.

4 January 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SGSarah B. Gitto
Sarah B. Gitto
VPVeethika Pandey
Veethika Pandey
JOJeremiah L. Oyer
Jeremiah L. Oyer
ACAlicja J Copik
Alicja J Copik
FHFrederick C. Hogan
Frederick C. Hogan
DADeborah Anne Altomare
Deborah Anne Altomare